At a glance

Type

Medicine / medicine family

Regulatory context

United States: this overview describes the cited product-specific prescribing information. It is not a statement of Thai approval or current commercial availability.

Evidence

The strongest evidence concerns HIV-associated abdominal fat accumulation. A reduction in visceral fat is not equivalent to general weight loss or a proven cardiovascular benefit.

What it is

Tesamorelin stimulates the growth-hormone axis through a growth-hormone-releasing-factor analogue. Egrifta WR is labelled in the United States for excess abdominal fat in adults with HIV-associated lipodystrophy, not routine weight management. The label explicitly says WR and SV are not substitutable. [1]

What the research shows

A 26-week placebo-controlled trial enrolled 412 people with HIV and abdominal fat accumulation; 86% were men. Visceral adipose tissue, measured by CT, fell by 15.2% with tesamorelin and rose by 5.0% with placebo. This was a change in a specific fat compartment, not the same percentage change in total body weight. [2]

What follow-up can tell us

A separate randomised trial in 404 people with HIV-associated central fat accumulation included a safety extension. It reported reduced visceral fat and improvements in body-image distress. These results support a defined clinical context; they do not demonstrate that healthy adults seeking cosmetic fat loss obtain the same balance of benefit and risk. [3]

What remains uncertain

A surrogate or imaging endpoint can be useful without proving fewer heart attacks, longer life or a broad anti-ageing effect. Generalising beyond the studied population requires additional evidence. The named formulation and its current prescribing information matter as much as the molecule name. [1] [2] [3]

Questions for your doctor

Is the specific HIV-associated lipodystrophy indication relevant? Which formulation is being considered? How will glucose, IGF-1, relevant cancer history and treatment response be assessed? Do not infer a dosing schedule from a catalogue vial size. [1]

Safety and clinical context

The Egrifta WR label contraindicates use in pregnancy, active malignancy, relevant hypothalamic-pituitary disorders and known hypersensitivity. It calls for attention to elevated IGF-1, glucose intolerance or diabetes, fluid retention and allergic reactions. Long-term cardiovascular safety is not established. [1]

Evidence and authorisation depend on the product, formulation, indication and country. US labelling does not establish Thai authorisation. This guide is educational and is not a dosing or self-treatment protocol.